Metformin Recall Alert: Current Safety and Quality Risks

Between February 2020 and January 2022, the FDA recalled 281 metformin extended-release products after testing revealed contamination with a probable carcinogen called N-nitrosodimethylamine, or NDMA. The contamination was not a one-off manufacturing error but part of a broader pattern affecting several drug classes, and the underlying chemistry that produces NDMA in metformin tablets turns out to be surprisingly difficult to eliminate. For the millions of people who rely on metformin daily to manage type 2 diabetes, the recalls raised urgent questions about whether their pills are safe and what, if anything, they should do differently.

What NDMA Is and Why Regulators Flagged It

NDMA belongs to a family of chemicals called nitrosamines, which are classified as probable human carcinogens. You encounter tiny amounts of NDMA in everyday life through grilled meats, beer, cigarette smoke, and even drinking water, but the doses are generally low enough that your body handles them without measurable harm. The concern with pharmaceuticals is different: if you take a contaminated pill every day for years, the cumulative exposure adds up. The FDA and European Medicines Agency both set an acceptable daily intake limit for NDMA in metformin at 96 nanograms per day, an amount based on the level believed to cause fewer than one additional cancer case per 100,000 people over a lifetime of exposure.

Animal studies have consistently shown that NDMA’s cancer-causing effects track with cumulative dose rather than daily dose alone. Research using sensitive mutation-detection methods found that short, high-dose exposures and longer, lower-dose exposures produced nearly identical mutation burdens in liver tissue when the total amount of NDMA was the same.

Scope of the Recalls

Metformin was not the first drug caught up in the nitrosamine crisis. Starting in 2018, several blood-pressure medications in the sartan family were pulled from shelves for NDMA or a related contaminant, followed by the heartburn drug ranitidine. By the time regulators turned their attention to metformin in late 2019, the FDA’s recall database already listed more than 1,400 product lots withdrawn across multiple drug classes for nitrosamine levels above acceptable limits.¹ International regulators coordinated their testing, and recalls of certain metformin batches followed after NDMA was confirmed above the 96-nanogram-per-day threshold.²

The 281 metformin extended-release products recalled over roughly two years represented a significant fraction of the ER market.³ Immediate-release metformin, which is the more commonly prescribed form, was largely spared from formal recalls, though not entirely free of detectable NDMA. The distinction between extended-release and immediate-release products became one of the most important practical details for patients trying to figure out whether their specific prescription was affected.

Why Extended-Release Products Were Hit Harder

A recurring finding across multiple studies is that NDMA contamination concentrates in finished tablets rather than in the raw metformin ingredient itself. When researchers tested the active pharmaceutical ingredient before it was pressed into tablets, NDMA was typically undetectable. But once that same ingredient was formulated into finished products, NDMA appeared in the vast majority of samples. In one large testing effort, NDMA showed up in about 85% of standard finished-product samples and roughly 92% of prolonged-release samples.⁴

Extended-release tablets consistently fared worse than immediate-release ones. In an analysis of crowdsourced metformin tablets from people across the United States, about 31% of extended-release samples had NDMA concentrations that would exceed the acceptable daily intake at maximum prescribed doses. Among immediate-release tablets, none crossed that threshold.⁵ The likely explanation comes down to how the two formulations are manufactured. Extended-release tablets require additional processing steps, different excipients, and sometimes higher temperatures during production, all of which feed the chemical reaction that generates NDMA.

That said, the picture is not perfectly clean for immediate-release products either. Stability testing of ten FDA-approved metformin products found that two immediate-release products had NDMA levels well above the acceptable limit before any storage stress was applied. One contained roughly 12 times the limit, and another contained about 39 times the limit per tablet.⁶ So the extended-release pattern holds as a general trend, but specific products of any formulation type can be outliers.

How NDMA Forms in Metformin Tablets

Understanding how NDMA gets into metformin tablets matters because it explains why the problem has been persistent and why it does not simply go away by sourcing “cleaner” raw ingredients. The raw metformin molecule is not the issue. Instead, NDMA is generated during the tablet-making process through a reaction involving trace amounts of dimethylamine, a byproduct left over from metformin synthesis, and nitrite or nitrate, which are present in tiny quantities in common tablet excipients like fillers and binders.

Research has confirmed that water, heat, and the nitrite and nitrate content of excipients are the key ingredients that must be present together for NDMA to form during manufacturing.⁷ Wet granulation, a step in which ingredients are mixed with a liquid binder and then dried with heat, creates ideal conditions. The heat drives the nitrosation reaction, and even trace-level nitrite can produce NDMA when dimethylamine is available. Researchers have also identified a separate pathway in which nitrogen dioxide from ambient air reacts with dimethylamine on the tablet surface, meaning that even post-manufacturing exposure to certain atmospheric conditions can contribute.⁸

Reducing NDMA, therefore, requires tackling both sides of the reaction: keeping dimethylamine residues in the raw ingredient as low as possible and selecting excipients with minimal nitrite and nitrate content. Both of these interventions have been shown to be effective in controlled studies.⁹ The practical challenge is that excipient suppliers do not always guarantee nitrite levels, and dimethylamine is a natural byproduct of metformin’s chemical synthesis that can only be reduced, not entirely eliminated.

Packaging as a Surprise Source

In at least one investigated case, NDMA and a related contaminant showed up in finished tablets even though the bulk drug product was clean before packaging. The source turned out to be the blister pack itself. Nitrocellulose, a compound used as a primer in the lidding foil of certain blister packaging, can act as a nitrosating agent when it comes into contact with secondary amines in printing inks. The resulting nitrosamines migrated from the foil into the tablet cavity and contaminated the pills.¹⁰

This finding complicated the narrative that NDMA was purely a manufacturing problem. It meant that even a manufacturer who had optimized their formulation process could end up with contaminated products because of packaging materials sourced from a different supplier. Higher vapor amounts of nitrosamines were detected on plate-sealing equipment, suggesting that the heat used to seal blister packs was accelerating the reaction inside the packaging components themselves. For drugs dispensed in pharmacy vials rather than blister packs, this particular pathway is less relevant, but it highlighted how many points in the supply chain can introduce contamination.

Storage Conditions Make Things Worse

NDMA levels in metformin tablets are not static. Stability testing has shown that levels can climb during normal storage. In a study that repacked FDA-approved metformin products into standard pharmacy vials and stored them at conditions meant to simulate a warm, humid environment for 12 weeks, several products that started near or above the acceptable limit saw further increases.⁶ This is consistent with the chemistry: the reaction producing NDMA is ongoing as long as the precursors (dimethylamine and nitrite) are present and heat or humidity provides energy.

For patients, this has a practical implication. Storing metformin in a hot car, a steamy bathroom cabinet, or a non-climate-controlled environment could plausibly accelerate NDMA formation compared to a cool, dry spot. The effect has not been quantified precisely for every product, but the direction of the relationship is clear from the lab data.

How Manufacturers Are Reformulating

The pharmaceutical industry has not been standing still. Multiple research groups have explored adding antioxidants to metformin formulations to interrupt the chemical reaction that produces NDMA. The approach works because antioxidants scavenge the reactive nitrogen species that would otherwise convert dimethylamine into NDMA. In one study, antioxidants like ascorbic acid, caffeic acid, and ferulic acid were tested at various concentrations in metformin tablets deliberately spiked with sodium nitrite to simulate worst-case conditions. At higher concentrations, all tested antioxidants achieved complete suppression of NDMA formation. Formulations with a basic pH environment were also effective even without antioxidants.¹¹

A separate study evaluated trolox (a water-soluble vitamin E analog), ascorbic acid, and alpha-tocopherol under both accelerated and long-term storage conditions. Trolox at a 5% concentration achieved the strongest inhibition, reducing NDMA formation by about 62% under accelerated storage conditions over 90 days. Trolox also reduced NDMA-induced DNA damage in cell-based genotoxicity assays and, unexpectedly, appeared to improve metformin’s intestinal absorption in a lab model.¹²

The catch with adding antioxidants is regulatory. Any change to a tablet’s excipient list can potentially affect how the drug dissolves and enters the bloodstream, which means the reformulated product may need to demonstrate bioequivalence to the original. Researchers have flagged the need for careful evaluation to ensure that the antioxidant strategy does not inadvertently change the drug’s clinical performance.¹³ This regulatory step takes time, which helps explain why the transition to cleaner formulations has been gradual rather than instant.

The Challenge of Detecting NDMA Accurately

Part of what made the metformin recall situation messy was that different laboratories, using different analytical methods, sometimes got different results for the same product. A comparison study across four laboratories and three companies found measurable disagreements depending on whether the lab used liquid chromatography or gas chromatography methods, and whether they employed tandem mass spectrometry or high-resolution mass spectrometry.¹⁴ Metformin itself is chemically tricky to work with because it can interfere with some detection methods, creating false positives or masking true contamination levels.

Newer methods have pushed sensitivity much lower. One technique using in-tube solid-phase microextraction coupled with mass spectrometry achieved detection limits as low as a few picograms per milliliter, sensitive enough to simultaneously screen for seven different nitrosamines in a single metformin tablet sample.¹⁵ These advances matter because regulators and manufacturers now have better tools to catch contamination before products reach pharmacy shelves, and to verify that mitigation strategies are actually working.

Should You Stop Taking Metformin?

This is the question that matters most to patients, and the answer from every major regulatory agency has been consistent: do not stop taking metformin without talking to your doctor. The reason is straightforward. Uncontrolled blood sugar is a known, well-quantified risk. The theoretical cancer risk from NDMA at the levels found in most metformin products, while nonzero, is orders of magnitude smaller than the cardiovascular, kidney, and nerve damage that comes from letting diabetes go untreated.

Data from the Diabetes Prevention Program illustrates why abruptly stopping metformin is a bad idea. In that large trial, people who stopped metformin during a washout period were diagnosed with diabetes at a notably higher rate than those who continued. The drug’s protective effect was partly pharmacological, meaning it only lasted as long as patients kept taking it. After the washout, the incidence of diabetes was still reduced by about 25% compared to placebo, but a meaningful chunk of the benefit disappeared when the drug was withdrawn.¹⁶

Real-world evidence from a Veterans Affairs healthcare network reinforced this concern. When metformin recalls forced some patients to switch medications, researchers tracked what happened to their blood sugar control. Patients who moved to GLP-1 agonists or SGLT-2 inhibitors generally maintained or improved their hemoglobin A1c levels. But those switched to insulin regimens saw their control worsen, and the disruption itself introduced a period of instability.¹⁷ The takeaway is not that alternative medications are bad, but that any forced, unplanned medication switch carries risks, and that patients and clinicians should weigh NDMA exposure against the concrete, immediate consequences of losing blood sugar control.

Metformin Adherence Was Already Fragile

The recall situation landed on top of an existing adherence problem. Even before the NDMA news, a large retrospective study found that about 36% of new metformin users discontinued the medication, and among those who continued, only around 40% to 44% were considered adherent by pharmacy refill records.¹⁸ Gastrointestinal side effects, cost, and general pill fatigue were already driving people off the drug. Adding contamination fears on top of that created a scenario where patients who were already ambivalent about their medication had a ready-made justification to stop.

Clinicians working with diabetic patients have had to walk a fine line: acknowledging the legitimacy of contamination concerns while emphasizing that the risk calculus still overwhelmingly favors continuing metformin or switching to a well-chosen alternative rather than going untreated. For patients who are anxious, asking your pharmacist which specific manufacturer your prescription comes from and whether that manufacturer’s lots have been part of any recall can provide concrete reassurance. Switching from an extended-release formulation to immediate-release, if clinically appropriate, is another conversation worth having with your prescriber, given the consistently lower NDMA levels seen in IR products.

The Broader Nitrosamine Problem in Pharmaceuticals

Metformin’s NDMA issue is not unique. The same class of contaminants has affected blood pressure medications, heartburn drugs, and other widely used products.¹⁹ The root causes vary by drug. For the sartans, the contamination originated during synthesis of the active ingredient itself. For ranitidine, the molecule was inherently unstable and generated NDMA under normal storage conditions, which ultimately led to a full market withdrawal. Metformin’s situation falls somewhere in between: the raw ingredient is clean, but the manufacturing process and even the packaging materials can introduce contamination.

What ties these cases together is that the pharmaceutical industry and regulators did not routinely test for nitrosamines until the sartan crisis forced the issue. The analytical methods existed, but they were not part of standard quality-control protocols. Since 2020, the FDA has required manufacturers of all drugs to assess their products for nitrosamine risk and test accordingly. The European Medicines Agency imposed similar requirements. This means the current generation of metformin products entering the market is being scrutinized far more carefully than anything sold before 2020, and the testing infrastructure is now sensitive enough to catch contamination at levels that would have gone unnoticed a decade ago.